Not applicableApproved For MarketingNCT04829422What this trial is testingEarly Access Program of Lazertinib in Republic of KoreaWho this might be right forLung Cancer Yuhan Corporation
Early research (Phase 1)Study completedNCT02947386What this trial is testingNimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung CancerWho this might be right forEGFR Gene MutationRecurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung Cancer+2 more Roswell Park Cancer Institute 7
Large-scale testing (Phase 3)Looking for participantsNCT06043973What this trial is testingAlmonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung CanceWho this might be right forAdvanced Non-small Cell Lung Cancer Qianfoshan Hospital 98
Large-scale testing (Phase 3)Study completedNCT02352948What this trial is testingA Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerWho this might be right forNon - Small Cell Lung Cancer NSCLC AstraZeneca 597
Early research (Phase 1)Looking for participantsNCT06050980What this trial is testingPhase I Study of HSK40118 in NSCLC Patients With EGFR MutationWho this might be right forNSCLC Haisco Pharmaceutical Group Co., Ltd. 220
Testing effectiveness (Phase 2)UnknownNCT03267654What this trial is testingGefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation AbundanceWho this might be right forNon-small-cell Lung Cancer Qilu Pharmaceutical Co., Ltd. 100
Testing effectiveness (Phase 2)UnknownNCT04785729What this trial is testingAlmonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI ResistanceWho this might be right forSafety Sun Yat-sen University 36
Testing effectiveness (Phase 2)UnknownNCT02375022What this trial is testingRh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR MutationsWho this might be right forLung Cancer Zhejiang University 10
Large-scale testing (Phase 3)Looking for participantsNCT06735391What this trial is testingA Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsWho this might be right forLocally Advanced or Metastatic Non-squamous NSCLCHarboring EGFR Sensitive Mutations NSCLCPreviously Untreated Systematically NSCLC Shanghai JMT-Bio Inc. 516
Large-scale testing (Phase 3)Not Yet RecruitingNCT06970782What this trial is testingVebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI FailureWho this might be right forNon-Small-Cell Lung Cancer Avistone Biotechnology Co., Ltd. 278
Testing effectiveness (Phase 2)Looking for participantsNCT07117890What this trial is testingSunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon MutationsWho this might be right forNon Small Cell Lung Cancer Fudan University 34
Not applicableStudy completedNCT04552613What this trial is testingEfficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC PatientsWho this might be right forNon-small-lung-cell CancerNSCLCEGFR Gene Mutation The Fourth Affiliated Hospital of Zhejiang University School of Medicine 114
Testing effectiveness (Phase 2)Active Not RecruitingNCT06015503What this trial is testingA Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)Who this might be right forNSCLC (Non-small Cell Lung Cancer) Avistone Biotechnology Co., Ltd. 139
Testing effectiveness (Phase 2)Looking for participantsNCT06276283What this trial is testingDZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)Who this might be right forNon-small Cell Lung Cancer Dizal Pharmaceuticals 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06940401What this trial is testingJS111 in Patients With Advanced NSCLC Harboring EGFR MutationsWho this might be right forNSCLC Suzhou Junjing BioSciences Co., Ltd. 44
Testing effectiveness (Phase 2)Ended earlyNCT03805841What this trial is testingStudy of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene FusionsWho this might be right forNSCLC, Stage IVNSCLC Stage IIIBNSCLC, Stage IIIC+5 more Rain Oncology Inc 41
Testing effectiveness (Phase 2)UnknownNCT02811354What this trial is testingPhase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNAWho this might be right forCarcinoma, Non-Small-Cell Lung National University Hospital, Singapore 108
Testing effectiveness (Phase 2)Study completedNCT01982955What this trial is testingTepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)Who this might be right forNon-small Cell Lung Cancer Merck KGaA, Darmstadt, Germany 88
Early research (Phase 1)Study completedNCT03446417What this trial is testingZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Zeno Pharmaceuticals, Inc. 34
Not applicableStudy completedNCT02991274What this trial is testingARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central LaboratoryWho this might be right forLocally Advanced or Metastatic EGFR(+) NSCLC Patients AstraZeneca 897